Company intelligence / Profile preview

Epitomee Medical

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Epitomee’s flagship product—the Epitomee Capsule—received FDA clearance in September 2024 as a prescription, drug-free ingestible medical device for weight management in adults with BMI 25–40 kg/m². Clinical trials showed statistically significant but modest weight loss (~2% over placebo); about 27% of patients lost at least 10% of body weight and >10% lost at least 15%. The company also develops an ingestible platform for oral delivery of biologics[5][6][8].

Therapeutic areas: OtherEndocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Epitomee Capsule

Commercial

Indications: Weight management, Diabetes prevention

Partnerships

Previously had a commercialization agreement with Nestlé; currently seeking new strategic partners after Nestlé withdrew

Beyond the preview

Go deeper on Epitomee Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epitomee Medical.

Explore the full profile